Streptococcus

New study reveals ThymoQuin® with Omega-3 Aids in Sports Immunity & Wellbeing

Retrieved on: 
Wednesday, October 12, 2022
TQ, Seed, GC, Fatty acid, Trial of the century, Exercise, Health, Nigella sativa, Thymoquinone, Streptococcus thermophilus, CEO, Patent, Athlete, Overalls, Harrison, Skin, GLOBE, ATP, Ageing, Scalp, Dietary supplement, Nigella, Streptococcus

The study results showed that the athlete participants had improved immune systems and overall mental well-being.

Key Points: 
  • The study results showed that the athlete participants had improved immune systems and overall mental well-being.
  • Stress-related gut imbalances and immune changes can represent significant challenges for athletes exercise performance and overall health and well-being.
  • In the study, researchers used the exercise stress of endurance running to challenge gut microbiome resilience and temporarily suppress immune vigilance.
  • To learn more about ThymoQuin, visit TriNutra.com or contact TriNutras exclusive U.S. distribution partner, Barrington Nutritionals .

Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumoni

Retrieved on: 
Wednesday, October 12, 2022
IND, Eagle, University, European Medicines Agency, Patent, Phrase, Food and Drug Administration Safety and Innovation Act, Nebraska Medicine, Failure, Genta (company), Biomarker, University of Nebraska Medical Center, Infection, The New England Journal of Medicine, Jean-Louis Vincent, Streptococcus, Pneumonia, Regulation of tobacco by the U.S. Food and Drug Administration, Drug development, MPH, Private Securities Litigation Reform Act, Company, P, S, GLOBE, FDA, Hospital, Annual report, Critical care, Research, Security (finance), U.S. Securities and Exchange Commission, CNS, Death, Compliance, Physician, Disease, Community-acquired pneumonia, SEC, Finelli, Patient, Nasdaq, Food, Tariff, Safety, Bronchopneumonia, Forward-looking statement, COVID-19, Pharmaceutical industry, Santu Mofokeng, Medicine, MD

WOODCLIFF LAKE, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that it has submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia (“SCABP”).

Key Points: 
  • CAL02 is a very interesting agent with a unique mechanism of action.
  • CAL02 has the potential to shift the treatment paradigm for patients with severe community-acquired pneumonia, a leading cause of death worldwide.
  • In addition, Eagle believes a CAL02 new drug application for the treatment of SCABP may qualify for priority review.
  • 2 Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., ... & Finelli, L. (2015).

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona

Retrieved on: 
Tuesday, October 11, 2022
U.S. Securities and Exchange Commission, Water, Sepsis, Inactivated vaccine, Congress, Streptococcus pneumoniae, Risk, Media, SEC, Government, Cincinnati Children's Hospital Medical Center, Hospital, Vaccine, VLP, Research, Security (finance), Malaria, Nose, AOM, Subclinical infection, S&P, Private Securities Litigation Reform Act, Infection, University, Center, OH, American Lung Association, BWV, Nov, St. Jude Children's Research Hospital, Sinusitis, Bacteria, GLOBE, Korea Disease Control and Prevention Agency, Vaccination, Norovirus, Jude the Apostle, FDA, COVID-19, Pharmaceutical industry, Streptococcus

Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis.

Key Points: 
  • Non-invasive forms of pneumococcal disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis.
  • BWVs new development plan aims to assess the efficacy of BWV-201 in protecting individuals against non-invasive pneumococcal pneumonia.
  • BWV-201 is a live attenuated bacterial vaccine candidate developed for the prevention of AOM in children caused by Streptococcus pneumoniae.
  • While current pneumococcal vaccines have demonstrated excellent efficacy against invasive pneumococcal disease historically, pneumococcal pneumonia remains a significant unmet medical need, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.

New Research Shows Rare Gene Variants Can Impact Neuropsychiatric Disorders Triggered By Strep And Other Infections

Retrieved on: 
Friday, October 7, 2022
Physician, Lists of diseases, PANDAS, Infection, Parent, Patient, Lyme disease, Treating, MD, DRS, Strep, Doctor of Philosophy, Pediatrics, Awareness, Bacteria, Brain, Anxiety, Autism, Tic, Gene, OCD, Pharmaceutical industry, Vaccine, PANS, Streptococcus

PORTSMOUTH, N.H., Oct. 7, 2022 /PRNewswire-PRWeb/ -- Researchers from the US and the Netherlands released new findings at a symposium in Portsmouth, New Hampshire that could impact future testing for post-infectious neuropsychiatric disorders called PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)

Key Points: 
  • Says Lachman, "These problems create PANS skepticism among physicians, preventing PANS patients from getting proper care.
  • One way to address this conundrum is to identify genes that might be involved in the predisposition to develop PANS."
  • In addition, overlap was found between the mutations that increase PANS susceptibility with autism spectrum disorders and immune disorders.
  • The team released their findings at the symposium, entitled PANDAS/PANS: Recognizing, Understanding and Treating Immune-Mediated Neuropsychiatric Disorders in Portsmouth, New Hampshire last week.

Dr. B Dental Solutions Announces Partnership with Affordable Dentures & Implants

Retrieved on: 
Tuesday, October 4, 2022
Palate, American Dental Association, Breast implant, Liquid crystal, Escherichia coli, Face, Coconut oil, Stomatitis, Dentures, Plaque, Xerostomia, Family, Aloe vera, Aloe, Tongue, Candida albicans, Vitamin and mineral supplementation for dialysis patients, USB, Staphylococcus, Partnership, Infection, ADA, Mouth, Patient, Powder, Tablet, Dentistry, Plaster, Pneumonia, Streptococcus, Implant

Dallas, Texas--(Newsfile Corp. - October 4, 2022) - Dr. B Dental Solutions has announced a partnership with Affordable Dentures & Implants.

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - October 4, 2022) - Dr. B Dental Solutions has announced a partnership with Affordable Dentures & Implants.
  • Affordable Dentures & Implants, with almost 400 dental practices spread across 40 states, is the largest provider of dentures and dental implants in the world .
  • As a result of the partnership, Dr. B Affordable Dentures Kits, with all six Dr. B.
  • Dr. B Dental Solutions has a complete range of products for people with dentures and oral appliances.

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Retrieved on: 
Monday, October 3, 2022
Urinary tract infection, FSE, Cystic fibrosis, GLOBE, Pyelonephritis, Recce, UTI, Infection, Urine, Streptococcus, Degenerative disease, RCE, Virus, Synthetic, FDA, ASX, GAIN, Gram-negative bacteria, Burn, Male, Mycobacterium abscessus, Bacteria, DFU, Sepsis, Safety, Streptococcus pneumoniae, Time-invariant system, Sydney, Pew, Patient, Kidney, Diabetic foot ulcer, Woman, Helicobacter pylori, Company, Pharmaceutical industry, Antibiotics, Vaccine

SYDNEY Australia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.

Key Points: 
  • We have therefore established an ambitious development plan, aiming to get new anti-infective therapies into market as expediently possible.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

5 Steps for Women to Reduce Their Risk of COPD

Retrieved on: 
Thursday, September 29, 2022
People, Disability, Vaccine-preventable diseases, Smoke, COVID-19, Woman, Risk, National Heart Valve Disease Awareness Day, Herbal cigarette, Smoker, Life, Air pollution, News, Microsoft family features, Learning, Streptococcus, Lung, Exercise, National Heart, Lung, and Blood Institute, Wheeze, Degenerative disease, Sleep, Chronic obstructive pulmonary disease, COPD, Smoking, Man, Disease, Death, Tobacco, Pharmaceutical industry

Chronic obstructive pulmonary disease (COPD), a leading cause of disability and death in the United States, takes an especially heavy toll on women.

Key Points: 
  • Chronic obstructive pulmonary disease (COPD), a leading cause of disability and death in the United States, takes an especially heavy toll on women.
  • Women tend to develop COPD earlier in life than men and are more likely to have severe symptoms and be hospitalized with the disease.
  • According to the National Heart, Lung, and Blood Institute, there are steps you can take to reduce your risk for COPD.
  • Women with COPD tend to be diagnosed later than men when the disease is more severe and treatments are less effective.

Global Pneumococcal Vaccine Market Report 2022: Escalating Birth Rates & Rising Parental Concerns Fuel Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Health, Pharmaceutical, Health, COVID-19, Risk, PCV, Infant, World, World Health Organization, Smoker, Immunization, Streptococcus, WHO, Parent, Streptococcus pneumoniae, Disease, CAGR, Vaccine, Growth

The "Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global pneumococcal vaccine market size reached US$ 8.5 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 11.6 Billion by 2027, exhibiting a CAGR of 5.32% during 2021-2027.
  • Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth.

Global Pneumococcal Vaccines Market Report (2022 to 2027) - Growing Incidence of Childhood Pneumonia is Driving the Industry - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Health, Pharmaceutical, Streptococcus, Incidence, Child, UNDP, COVID-19, PCV, FDA, UNICEF, Disease, Food, Central African, Vaccination, Immunization, GSK, Growth, Conjugate vaccine, Government, Regulation of tobacco by the U.S. Food and Drug Administration, Serum Institute of India, Serum, Pneumonia, Vaccine, AstraZeneca, PATH, Inactivated vaccine, WHO, Infection, Streptococcus pneumoniae, Fatality, Bill & Melinda Gates Foundation, Awareness, Mortality, Merck, Pfizer, Death, Pharmaceutical industry

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines.

Key Points: 
  • Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines.
  • Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death.
  • Pneumonia vaccines are primarily given to children under two years and adults 65 years and older.
  • The market leaders for the Global Pneumococcal Vaccines Market are Pfizer, GSK, Merck Serum Institute of India Pvt Ltd, and AstraZeneca.

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

Retrieved on: 
Monday, September 19, 2022
Health, Consumer, Infectious Diseases, Children, Clinical Trials, Pharmaceutical, Biotechnology, Streptococcus, Safety, Immunoglobulin G, OPA, Development, GMC Terrain, 2020 European Medicines Agency cyberattack, Infant, NI, Vaccination, Population, Senior, Clinical trial, Pneumonia, Vaccine, European Medicines Agency, Streptococcus pneumoniae, IPD, EMA, Pharmaceutical industry, Pfizer

Phase 3 study in infants (NCT04546425) evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

Key Points: 
  • Phase 3 study in infants (NCT04546425) evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
  • For the NI co-primary objective of IgG GMCs one month after Dose 2, 16 of the 20 serotypes met NI.
  • Pfizer plans to file these data by the end of this year with the European Medicines Agency (EMA).
  • In 2020, Pfizer initiated the Phase 3 clinical trial program for the pediatric indication for 20vPnC.